Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MYNZ NYSE:NNVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMYNZMainz Biomed$0.40-2.6%$0.61$0.55▼$4.43$3.62M0.31371,589 shs354,476 shsNNVCNanoViricides$1.46-2.7%$1.08$0.85▼$2.23$31.53M1.54273,568 shs410,661 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMYNZMainz Biomed0.00%-19.11%-10.37%-63.66%-85.59%NNVCNanoViricides0.00%+4.00%+39.74%+34.92%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMYNZMainz Biomed$0.40-2.6%$0.61$0.55▼$4.43$3.62M0.31371,589 shs354,476 shsNNVCNanoViricides$1.46-2.7%$1.08$0.85▼$2.23$31.53M1.54273,568 shs410,661 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMYNZMainz Biomed0.00%-19.11%-10.37%-63.66%-85.59%NNVCNanoViricides0.00%+4.00%+39.74%+34.92%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMYNZMainz Biomed 1.50ReduceN/AN/ANNVCNanoViricides 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MYNZ and NNVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2026MYNZMainz Biomed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMYNZMainz Biomed$659.94K5.49N/AN/A$2.61 per share0.15NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ANNVCNanoViricides-$8.29M-$0.48N/AN/AN/AN/A-87.90%-78.69%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMYNZMainz BiomedN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMYNZMainz Biomed0.440.520.43NNVCNanoViricidesN/A3.442.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMYNZMainz BiomedN/ANNVCNanoViricides10.30%Insider OwnershipCompanyInsider OwnershipMYNZMainz Biomed18.20%NNVCNanoViricides3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableNNVCNanoViricides2021.60 million14.92 millionOptionableMYNZ and NNVC HeadlinesRecent News About These CompaniesNanoViricides (NYSE:NNVC) Shares Up 15.4% - Time to Buy?May 5 at 2:09 AM | americanbankingnews.comNanoViricdes Surges on Winning ODD StatusMay 4 at 6:17 PM | baystreet.caNNVC stock up 17% today: What’s driving the rally?May 4 at 6:17 PM | msn.comNanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatmentMay 4 at 9:14 AM | proactiveinvestors.comNV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDAMay 4 at 8:30 AM | accessnewswire.comADeadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricidesApril 21, 2026 | usatoday.comNanoViricides says NV-387 could address measles outbreaks as cases rise globallyApril 21, 2026 | proactiveinvestors.comDeadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricidesApril 21, 2026 | accessnewswire.comANanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMIApril 11, 2026 | finance.yahoo.comNanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMIApril 11, 2026 | proactiveinvestors.comNanoViricides files for Rare Pediatric Disease Designation for Measles DrugApril 9, 2026 | finance.yahoo.comNanoViricides seeks rare pediatric disease status for measles drug NV-387April 7, 2026 | proactiveinvestors.comMeasles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricidesApril 7, 2026 | accessnewswire.comASmall caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power XApril 1, 2026 | proactiveinvestors.comNanoViricides to begin Phase II trial of MPox treatment in CongoApril 1, 2026 | proactiveinvestors.comPhase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricidesApril 1, 2026 | accessnewswire.comANanoViricides Presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 – Announces Manufacture of Phase II Clinical Product NV-387 Oral ...March 11, 2026 | freep.comFNanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trialMarch 11, 2026 | proactiveinvestors.comNanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is CompleteMarch 11, 2026 | accessnewswire.comANanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMIFebruary 21, 2026 | proactiveinvestors.com2 Small-Cap Biotechs That Could Reward Patient Investors...December 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ and NNVC Company DescriptionsMainz Biomed NASDAQ:MYNZ$0.40 -0.01 (-2.58%) As of 05/4/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.NanoViricides NYSE:NNVC$1.46 -0.04 (-2.67%) Closing price 04:00 PM EasternExtended Trading$1.45 -0.01 (-0.75%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
